Cypress Eyeing $200-400 Mil. Prosorba Sales Based On 1-2% Of RA Market
This article was originally published in The Gray Sheet
Executive Summary
Cypress Bioscience expects its Prosorba column for treatment of rheumatoid arthritis to be a $200-400 mil. product by 2003, the company said following FDA's premarket approval of the device March 16. The PMA was submitted last July.
You may also be interested in...
Cypress Bioscience Prosorba Rheumatoid Arthritis Trial Gets HCFA Nod
Unpublished information generated in Cypress Bioscience's Prosorba clinical trial for rheumatoid arthritis was instrumental in the Health Care Financing Administration's decision to cover treatment for the Medicare population.
Cypress Bioscience Prosorba Rheumatoid Arthritis Trial Gets HCFA Nod
Unpublished information generated in Cypress Bioscience's Prosorba clinical trial for rheumatoid arthritis was instrumental in the Health Care Financing Administration's decision to cover treatment for the Medicare population.
HCFA Commits To Coverage Decision On Prosorba For Rheumatoid Arthritis
Cypress Bioscience will submit data used to obtain FDA approval of the Prosorba column for rheumatoid arthritis (RA) in an upcoming review for national Medicare coverage by the Health Care Financing Administration, the company reported Feb 22.